Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765063 and Ezabenlimab Combinations in Advanced HNSCC and HCC
NCT05249426Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2022
- Primary completion
- Jul 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 1, open-label trial of BI 765063 in head and neck squamous cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC) (5 cohorts), sponsored by Boehringer Ingelheim. Primary endpoint: Objective Response up to 24 months. Started Apr 2022; status: completed.
02
Drugs
BI 765063
03
Conditions
head and neck squamous cell carcinoma (HNSCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05249426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05249426.